Fullhope Biomedical Co

Fullhope Biomedical Co EPS

The Earnings per Share (EPS) of Fullhope Biomedical Co (7773.TWO) as of Oct 28, 2026 is -1.40 TWD. In the previous year, Earnings per Share (EPS) was -1.05 TWD — a change of 33.94% (lower).

EPS

-1.40TWD

YoY

33.94%

Last updated:

Earnings per Share (EPS) of Fullhope Biomedical Co is 2024 -1.40 TWD. Earnings per Share (EPS) of Fullhope Biomedical Co was 2023 -1.05 TWD. It decreases by 33.94% lower compared to the previous year.

The Fullhope Biomedical Co EPS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EPS
Date
EPS
Jan 1, 2022
-1.10 TWD
Jan 1, 2023
-1.05 TWD
Jan 1, 2024
-1.40 TWD
The Fullhope Biomedical Co EPS history
YEAREPSYoY
-1.40TWD+33.94%
-1.05TWD-4.60%
-1.10TWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Fullhope Biomedical Co Stock analysis

What does Fullhope Biomedical Co do? Fullhope Biomedical Co Ltd generates revenue through precision diagnosis and regenerative medicine products. The company offers immune function analysis and circulating tumor cell analysis platforms for follow-up disease treatment strategies. In regenerative medicine, Fullhope operates a Good Tissue Practice (GTP) laboratory with a complete immune cell and stem cell manufacturing platform producing cell products. The company targets medical institutions and healthcare providers seeking advanced diagnostic and regenerative solutions. Fullhope Biomedical Co Ltd focuses on developing immune function analysis and circulating tumor cell analysis platforms within precision diagnosis. The regenerative medicine segment includes GTP-compliant laboratory services and cell product manufacturing. Medical institutions and healthcare providers are the primary customers purchasing these specialized diagnostic and regenerative medicine solutions. The company's revenue streams come from both precision diagnosis platforms and regenerative medicine services. Immune function analysis and circulating tumor cell analysis platforms provide comprehensive immune system and tumor cell data for treatment planning. GTP laboratory services and cell product manufacturing under regenerative medicine deliver specialized medical solutions to healthcare providers. Fullhope Biomedical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Fullhope Biomedical Co stock

Earnings per Share (EPS) of Fullhope Biomedical Co is -1.40 TWD in 2024.

Earnings per Share (EPS) of Fullhope Biomedical Co changed from -1.05 TWD to -1.40 TWD, representing a 33.94% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Earnings per Share (EPS) Fullhope Biomedical Co since 2006 – with annual values, charts, and detailed analysis.

Earnings per Share measures the portion of a company's profit allocated to each outstanding share. It is a key metric for assessing a company's profitability on a per-share basis.

EPS = Net Income / Shares Outstanding

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Fullhope Biomedical Co

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Fullhope Biomedical Co